Centre for Snakebite Research and Interventions, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
PLoS Negl Trop Dis. 2024 Oct 18;18(10):e0012570. doi: 10.1371/journal.pntd.0012570. eCollection 2024 Oct.
Variation in snake venoms is well documented, both between and within species, with intraspecific venom variation often correlated with geographically distinct populations. The puff adder, Bitis arietans, is widely distributed across sub-Saharan Africa and into the Arabian Peninsula where it is considered a leading cause of the ~310,000 annual snakebites across the region, with its venom capable of causing substantial morbidity and mortality. Despite its medical importance and wide geographic distribution, there is little known about venom variation between different B. arietans populations and the potential implications of this variation on antivenom efficacy.
We applied a range of analyses, including venom gland transcriptomics, in vitro enzymatic assays and reverse phase chromatography to comparatively analyse B. arietans venoms originating from Nigeria, Tanzania, and South Africa. Immunological assays and in vitro enzymatic neutralisation assays were then applied to investigate the impact of venom variation on the potential efficacy of three antivenom products; SAIMR Polyvalent, EchiTAb-Plus and Fav-Afrique.
Through the first comparison of venom gland transcriptomes of B. arietans from three geographically distinct regions (Nigeria, Tanzania, and South Africa), we identified substantial variation in toxin expression. Findings of venom variation were further supported by chromatographic venom profiling, and the application of enzymatic assays to quantify the activity of three pathologically relevant toxin families. However, the use of western blotting, ELISA, and in vitro enzymatic inhibition assays revealed that variation within B. arietans venom does not appear to substantially impact upon the efficacy of three African polyvalent antivenoms.
The large distribution and medical importance of B. arietans makes this species ideal for understanding venom variation and the impact this has on therapeutic efficacy. The findings in this study highlight the likelihood for considerable venom toxin variation across the range of B. arietans, but that this may not dramatically impact upon the utility of treatment available in the region.
蛇毒的变异在种间和种内都有很好的记录,种内毒液变异通常与地理上不同的种群相关。角蝰,Bitis arietans,广泛分布于撒哈拉以南非洲,并延伸到阿拉伯半岛,在该地区,它被认为是每年约 31 万例蛇咬伤的主要原因,其毒液能导致严重的发病率和死亡率。尽管它具有重要的医学意义和广泛的地理分布,但人们对不同 B. arietans 种群之间的毒液变异知之甚少,也不知道这种变异对抗蛇毒血清疗效的潜在影响。
我们应用了一系列分析方法,包括毒液腺转录组学、体外酶活性测定和反相色谱法,比较分析了来自尼日利亚、坦桑尼亚和南非的 B. arietans 毒液。然后应用免疫测定和体外酶中和测定来研究毒液变异对三种抗蛇毒血清产品的潜在疗效的影响;SAIMR 多价血清、EchiTAb-Plus 和 Fav-Afrique。
通过首次比较来自三个地理位置不同的地区(尼日利亚、坦桑尼亚和南非)的 B. arietans 毒液腺转录组,我们发现毒素表达存在显著差异。毒液变异的发现进一步得到了色谱毒液分析和应用酶活性测定来定量三种病理相关毒素家族活性的支持。然而,Western blot、ELISA 和体外酶抑制测定表明,B. arietans 毒液中的变异似乎并没有显著影响三种非洲多价抗蛇毒血清的疗效。
B. arietans 的广泛分布和医学重要性使其成为了解毒液变异及其对治疗效果影响的理想物种。本研究的结果强调了 B. arietans 范围内毒液毒素变异的可能性很大,但这可能不会对该地区现有治疗方法的应用产生重大影响。